Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 4/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25334294 | 0.82 | PSMB5 (0.41) | PDGFRBPDGFRAPSMB5HTR2CSLC18A3 | |
| SCHEMBL2207389 | 0.80 | SLC18A3 (0.50) | SLC6A4PDGFRBPDGFRAPSMB5HTR2C | |
| Bromide SCHEMBL9325723 | 0.79 | SLC18A3 (0.49) | SLC6A4PDGFRBPDGFRAPSMB5HTR2C | |
| SCHEMBL6311570 | 0.78 | QDPR (0.51) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL18318511 | 0.75 | DYRK1A (0.48) | PDGFRBPDGFRA | |
| SCHEMBL24837865 | 0.71 | SLC18A3 (0.48) | HTR1ASLC6A2SLC6A4HTR2CMKNK1 | |
| SCHEMBL16272073 | 0.71 | HTR2C (0.46) | HTR2CMKNK1MKNK2SLC18A3SIGMAR1 | |
| SCHEMBL21061439 | 0.70 | PSMB5 (0.46) | SLC6A4PDGFRBPDGFRAPSMB5 | |
| SCHEMBL2450688 | 0.70 | HTR6 (0.45) | HTR1AHTR2CHTR6TNKSTNKS2 | |
| SCHEMBL26570916 | 0.70 | PDGFRB (0.49) | PDGFRBPDGFRAJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10166226-B2 | CGRP receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-01-01 | — | — | US | disclosed |
| CN-108430991-A | CGRP receptor antagonist | 赫普塔瑞斯医疗有限公司 | 2018-08-21 | — | — | CN | disclosed |
| US-20180153876-A1 | CGRP Receptor Antagonists | NXERA PHARMA UK LIMITED (GB) | 2018-06-07 | — | — | US | disclosed |
| US-9925178-B2 | CGRP receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-03-27 | — | — | US | disclosed |
| US-20170239236-A1 | CGRP Receptor Antagonists | NXERA PHARMA UK LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| US-9688660-B2 | CGRP receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180153876-A1 | CGRP Receptor Antagonists | CALCRL, CNR1, GALR1 | MPO 2360/4885HTR1A 31/4885SLC6A2 624/4885 |
| US-20170239236-A1 | CGRP Receptor Antagonists | CALCRL, CNR1, GALR1 | MPO 2360/4885HTR1A 31/4885SLC6A2 624/4885 |
| US-10166226-B2 | CGRP receptor antagonists | CALCRL, CNR1, GALR1 | MPO 2360/4885HTR1A 31/4885SLC6A2 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.